ClinicalTrials.gg
RecruitingNCT07011147PREPARE 4 AIDUpdated Jun 11, 2026

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

An interventional study of Bionic Pancreas and Routine Care in Type 1 Diabetes (T1D), Type 2 Diabetes and Diabetes, Autoimmune, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.

Planned enrollment
3rd of 44
240 · median 44
Started
2026
with 2 others
No phase
25 of 58
6 open now
Primary completion
2027-06
later than 5 of 12 live
Registered
56th of 58
by date

Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 3rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 56th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, or all of them as a file.
02

Study summary

The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main question it aims to answer is:

Can the iLet BP by deployed in primary care settings to adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes)?

Researchers will compare 13-weeks of iLet BP use to routine care to see if iLet BP use has a greater reduction in HbA1c compared to13-weeks of routine care.

Participants will:

Use the iLet BP for 13-weeks or continue their routine care Be trained to use the study devices or continue their routine care Complete a virtual screening visit, mid-period follow up calls and a final visit Complete baseline CGM collection Complete surveys and fingerstick a1c blood tests Routine care participants will have the option to complete an observational extension phase where they will wear the iLet BP for 13-weeks

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Type 2 Diabetes
  • Diabetes, Autoimmune
  • Diabetes Mellitus
  • Diabetes Mellitus Type 2
  • Diabetes Mellitus, Type I
  • Diabetes, Type II
  • Diabetes
  • Diabetes Mellitus, Insulin-Dependent
  • Diabetes Mellitus Type II
  • Diabetes Type 2 on Insulin

Keywords

  • automated insulin delivery
  • type 1 diabetes
  • type 2 diabetes
  • bionic pancreas
  • closed loop
  • pancreas, artificial
  • t1d
  • t2d
  • diabetes
  • insulin
  • primary care
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at time of consent >18 and \<89 years
  2. Either 2.a. or 2.b.:

    1. Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at least 1 year
    2. Clinical diagnosis of type 2 diabetes, on current injected or infused insulin regimen for at least 3 months prior to screening (e.g., basal-bolus, basal only, or pre-mix)
  3. Stable doses of glucose lowering medications over the preceding 4 weeks as determined by Investigator, including GLP-1 receptor agonists (GLP-1 RA) and GLP-1/GIP RA agents
  4. Stable doses of weight loss medications (including GLP-1 RA and GLP-1/GIP RA agents) over the preceding 4 weeks as determined by the investigator.
  5. For those using the iLet Bionic Pancreas (during the RCT arm or observational extension phase), willingness to stay on current doses of medications throughout the study that may affect glycemia directly and/or indirectly, except for a dose reduction or discontinuation.
  6. Have a primary care clinician willing to refer them to the study, confirm their diabetes diagnosis (for example: type 1 diabetes or type 2 diabetes), and recommend and manage the iLet for the duration of the study
  7. Willing to comply with all study procedures for the duration of the study
  8. Willing to wear a Dexcom CGM device and iLet system for duration of time randomized to iLet use or OEP
  9. Willing to use the following insulin: lispro (including non-branded lispro and Humalog) or aspart (including non-branded aspart, Fiasp, and Novolog)
  10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
  11. Willing and able to sign and date the Form (ICF)
  12. If capable of becoming pregnant, willing and able to have pregnancy testing and use an acceptable method of during the study period

    a. Capable of becoming pregnant means that menstruation has started and the participant is not surgically sterile or (12 months without menses) b. Acceptable methods of contraception include: i. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).

    ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).

    iii. Placement of an intrauterine device or intrauterine hormone-releasing system.

    iv. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository).

    v. Has a vasectomized or sterile partner (where partner is sole partner of participant) and where vasectomy has been confirmed by medical assessment.

    vi. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study.

  13. Agreement to adhere to Lifestyle Considerations (see Section 5.3) throughout study duration
  14. Have hardware and internet access capable of 2-way video and audio communication

Exclusion criteria

Exclusion Criteria:

  1. Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory)
  2. Unable to speak and read English, as iLet BP support materials and device menus are currently available in English only
  3. Diagnosis of maturity-onset diabetes of the young (MODY)
  4. Plan to change usual diabetes regimen between screening and study randomization

    1. This would include changing from MDI to pump or from pump to MDI, starting a new class of type 2 diabetes medication, or starting or increasing GLP-1 RA or GLP-1/GIP RA medication
    2. This would NOT include changes to any insulin doses, including pump settings, short- and/or long-acting insulin doses and type of insulin; changing type 2 diabetes medication dosing (except GLP-1 RA or GLP-1/GIP RA); or changing type of type 2 diabetes medication within the same class
  5. Weigh more than 255 kg (561 pounds) as this is the maximum weight that can be entered into the iLet user interface
  6. History of bariatric surgery within 12 months prior to enrollment or plans for bariatric surgery within the period of study participation
  7. Current use of a closed-loop or hybrid closed-loop insulin delivery system that is not FDA-cleared (e.g. "DIY Loop", "AAPS", "iAPS" or "Open APS")
  8. Diagnosed blood disorder or dyscrasia associated with hemolysis, including for example: sickle cell disease and thalassemia, which in the Investigator's opinion could interfere with accuracy
  9. Planned use of hydroxyurea at any dose and/or of acetaminophen at doses exceeding 1 gram (1000 mg) every 6 hours.
  10. Plans to receive a blood transfusion over the course of the study or has received a transfusion within 3 months prior to enrollment
  11. Current participation in another diabetes-related clinical trial
  12. History of diabetes due to cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma, or history of complete pancreatectomy
  13. Have a history of intermittent oral or injectable treatment within 8 weeks prior to screening or plans to take intermittent oral or injectable glucocorticoid during the study (chronic, stable treatment is acceptable, unplanned use is acceptable)
  14. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) in the 6 months prior to screening, unrelated to an intercurrent illness or to a kinked, dislodged, or occluded cannula
  15. Established history of allergy or severe reaction to adhesive or tape that must be used in the study
  16. Treated currently or within the past 30 days prior to enrollment, or plan to begin treatment, with sulfonylurea, pramlintide, or SGLT-2 inhibitor medication
  17. Any planned surgery during the study that would be considered major in the opinion of the investigator
  18. Pregnant or lactating, or planning to become pregnant in the next 6 months
  19. Renal failure on dialysis or chronic renal disease with a or eGFR \<30mL/min (values within the last two years will be accepted; if none available or >2 years prior, participant will be instructed to obtain GFR or eGFR through their usual care provider and to make copy of result available to study team)
  20. Any condition or circumstance that, in the opinion of the site principal investigator, could interfere with the safe or effective completion of the study or which could compromise the results of the study c. Conditions to be considered by the investigator may include, but are not limited to, the following: i. Active clinical diagnosis of substance use disorder ii. Chronic use of opiates and/or benzodiazepines which, in the opinion of the investigator, might make it difficult for the participant to follow study procedures iii. Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6 METS) despite medical management, or within the last 12 months before screening, a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting iv. Known history of prolonged , malignant arrhythmia, or severe congenital heart disease v. Congestive heart failure with (NYHA) Functional Classification III or IV vi. History of or stroke in the last 12 months vii. Untreated or inadequately treated mental illness viii. History of untreated or inadequately treated eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia, or omission of insulin to manipulate weight ix. History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
  21. Plans to travel outside of the US and its territories for more than four weeks consecutively
  22. Plans not to have internet/video/phone access for more than one week consecutively
  23. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
  24. Previous use of the iLet for more than four weeks (including use of the commercially available iLet or prior participation in a study involving wearing the iLet for more than four weeks)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Bionic Pancreas

    Device: Bionic Pancreas

  • Active comparator
    Routine Care

    Other: Routine Care

Interventions

  • DeviceBionic Pancreas

    The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.

  • OtherRoutine Care

    Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.

06

What researchers measure

Primary outcomes

  1. HbA1c between the BP and RC groups

    Superiority testing for HbA1c at 13 weeks between the BP and RC groups using linear mixed effects regression models adjusting for baseline HbA1c.

    Time frame: RCT Week 13

  2. Percentage of Time With CGM Glucose <54 mg/dl

    Non-inferiority testing for ordinal TBR\<54mg/dL will be determined using a two-sided 95% confidence interval on the mean difference in % time \<54 mg/dL between BP and RC groups using a linear mixed effects regression model adjusting for baseline % time \<54 mg/dL, diabetes type, and clinical center.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

Secondary outcomes

  1. Percentage of Time With CGM Glucose in the 70-180 mg/dl Range

    Calculated from all individual CGM values from RCT weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  2. Percentage of Time in Tight Range With CGM Glucose in the 70-140 mg/dl

    Calculated from all individual CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  3. Mean CGM Glucose

    Individual CGM values from weeks 1-13 averaged together for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  4. Percentage of Time With CGM Glucose >250 mg/dl Range

    Calculated from all individual CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  5. Percentage of Time With CGM Glucose >180 mg/dl Range

    Calculated from all individual CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  6. Standard deviation of CGM glucose

    Calculated from mean CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  7. Percentage of Time With CGM Glucose Below <70 mg/dl Range

    Calculated from all individual CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  8. Percentage of Time With CGM Glucose Below <54 mg/dl Range

    Calculated from all individual CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

  9. Coefficient of variation of CGM glucose

    Calculated from mean CGM values from weeks 1-13 for each participant.

    Time frame: RCT Weeks 1-13 and OEP Weeks 13-26

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified glucose data and psychosocial data will be shared with research collaborators.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 17 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Apr 1, 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07011147
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jan 16, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Jessica Parascando, MPH
Contact
primarycarediabeteslab@cuanschutz.edu
303-724-9525 ext. x49525
Elizabeth Westfeldt, BSN, RN
Contact
elizabeth.westfeldt@cuanschutz.edu
303-724-9525 ext. x49525
Sean Oser, MD, MPH, CDCES
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion